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Safety and Efﬁcacy of Degradable vs. Permanent Polymer Drug-eluting stents A
meta-analysis of 18, 395 Patients from randomized trials
Zhaoxiaohui, Huanglan
Cardiovascular Department of Xinqiao Hospital, Third Military Medical University
Objectives: Degradable polymer drug-eluting stents (DP-DES) represents a promising
strategy to improve the delayed healing and hypersensitive reaction in the vessel.
However, the efﬁcacy and safety of DP-DES vs. permanent polymer drug-eluting
stents (PP-DES) are less well deﬁned. The aim of this meta-analysis was to compare
the total, short (<30days), mid (30 days-1year) and long (>1 year) term outcomes of
DP-DES vs. PP-DES.
Methods: PubMed, Embase, and Cochrane Central Register of Controlled Trials
(CENTRAL) were searched for randomized clinical trials to compare any of approved
DP- and PP-DES. Efﬁcacy endpoints were target-lesion revascularization (TLR) and
in-stent late loss (ISLL). Safety endpoints were death, myocardial infarction (MI),
composite of deﬁnite and probable stent thrombosis (ST). The meta-analysis included
19 RCTs (n¼18, 395) with interest results. As compared with DES, there was a
signiﬁcantly reduced very late ST (OR¼0.42, 95% CI 0.24-0.77, P¼0.852) and ISLL
(OR¼-0.07, 95% CI -0.12-0.02, P¼0.000) in DP-DES patients. However, there were
no difference for other safety and efﬁciency outcomes between DP-DES and PP-DES,
except that the stratiﬁed analysis showed a signiﬁcant decreased TLR with DP-DES as
compared to paclitaxel-eluting stent (OR¼0.41, 95% CI 0.20-0.81, P¼0.457).
Results: DP-DES is more effective in reducing very late ST and ISLL, as well as
comparable to PP-DES with regard to death, TLR and MI. Further large RCTs with
long-term follow-up are warranted to better deﬁne the relative merits of DP-DES.
Conclusions: DP-DES is more effective in reducing very late ST and ISLL, as well as
comparable to PP-DES with regard to death, TLR and MI. Further large RCTs with
long-term follow-up are warranted to better deﬁne the relative merits of DP-DES.
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Safety and Efﬁcacy of Polymer Free vs. Based Drug-eluting Stents A
Meta-Analysis of Randomized Trials
Zhao Xiaohui, Huang Lan
Cardiovascular Department of Xinqiao Hospital, Third Military Medical University
Objectives: Polymer free drug-eluting stents (PF-DES) have recently been developed
to improve the delayed healing and hypersensitive reaction in the vessel. However,
Uncertainty exists regarding the relative performance of PF-DES versus polymer
based-DES (PB-DES) in percutaneous coronary intervention. The aim of this study
was to perform a meta-analysis of randomized controlled trials (RCTs) comparing the
safety and efﬁcacy proﬁle of PF-DES vs. PB-DES.
Methods: PubMed, Embase, and Cochrane Central Register of Controlled Trials
(CENTRAL) were searched for RCTs that compared PF-DES and PB-DES, enrolling
at least 100 patients. Efﬁcacy endpoints were target-lesion revascularization (TLR)
and in-stent late loss (ISLL). Safety endpoints were cardiac death, death, myocardial
infarction (MI), composite of deﬁnite and probable stent thrombosis (ST). The meta-
analysis included 9 RCTs (n¼6364) with a median follow-up of 26 months clinical
outcomes and 7 RCTs (n¼5027) with interest angiography results. The results showed
that there was no difference between PF-DES and PB-DES with regard to cardiac
death, death, ST, MI, ISLL or TLR.
Results: PF-DES is comparable as PB-DES with regard to cardiac death, death, ST,
MI, ISLL and TLR. Further large RCTs with longer follow-up are warranted to better
deﬁne the relative merits of these drug-eluting stents.
Conclusions: PF-DES is comparable as PB-DES with regard to cardiac death, death,
ST, MI, ISLL and TLR. Further large RCTs with longer follow-up are warranted to
better deﬁne the relative merits of these drug-eluting stents.
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Up-regulation of caveolin-1 suppresses vascular smooth muscle cells proliferation
and neointimal formation in balloon injured rat carotid artery
Lu Wei, Huang Lan
Cardiovascular Department of Xinqiao Hospital, Third Military Medical University
Objectives: Caveolin-1 (cav-1) is the major coat protein responsible for caveolae
assembly, regulating signaling via protein-protein interactions with resident caveolar
proteins, but its biological mechanism in vascular smooth muscle cells (VSMCs) is
still unclear. The aim of this study was to evaluate the role of cav-1 on VSMCs
proliferation and the neointimal formation in balloon injured rat carotid artery.
Methods: Left common carotid arteries from Sprague - Dawley rats were injured by a
balloon catheter, and the injured arteries were incubated with 30 mL solution of
Ad-cav-1 adenoviral vectors, Ad-GFP adenoviral vectors or PBS for 30 min. The rats
were euthanized for morphometric and immunohistochemical analysis, real-time PCR
and western blot analysis at 2 weeks after balloon injury and gene transfer. The
cultured rat VSMCs transduced with Ad-cav-1 or Ad-GFP adenoviral vectors were
used for cell proliferation assay, real-time PCR and western blot analysis. The vascular
or intracellular ROS level was also detected.
Results: Adenoviral vectors encoding cav-1 cDNA could increase cav-1 expression
both in mRNA and protein levels in balloon injured artery walls and cultured rat
VSMCs. Upregulation of cav-1 signiﬁcantly suppressed VSMCs proliferation and
intimal formation. Over-expression of cav-1 could reduce vascular or intracellularJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BROS level and decrease the phosphorylation of the ERK1/2 in balloon injured artery
walls and cultured rat VSMCs.
Conclusions: Our study suggests that over-expression of cav-1 signiﬁcantly
suppresses VSMCs proliferation and progression of neointimal formation after
vascular injury.
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EPO prevents apoptosis via JAK2/STAT5 in experimental epilepsy
Li Jie1, Ma Baoxin2, Li Qun1, Wu Suisheng1
1First Hospital of Jilin University, 2Afﬁliated Hospital of Binzhou Medical College
Objectives: To investigate the protective effects of recombinant human erythropoietin
(rhEPO) and carbamylated EPO (CEPO) against myocardial cell apoptosis in epilepsy
and to explore potential mechanisms involved.
Methods: Rats were given an KA to induce epilepsy. Groups of rats were treated with
rhEPO or CEPO before induction of epilepsy, while additional rats were given a
caudal vein injection of AG490, a selective inhibitor of Janus kinase 2 (JAK2). At 0,
2, 6, 12 and 24 hours after onset of seizures, epileptic rats were killed for detection of
myocardial cell apoptosis by TUNEL assay, the expression of JAK2 and STAT5
mRNAs by in situ hybridization, and the expression of caspase-3, JAK2, and STAT5
proteins by immunohistochemistry and Western blot.
Results: Induction of epilepsy signiﬁcantly enhanced myocardial cell apoptosis and
up-regulated the expression of caspase-3 and JAK2 and STAT5a at both the mRNA
and protein levels. Pretreatment with either rhEPO or CEPO reduced the number of
apoptotic cells, down-regulated caspase-3 expression in the myocardium of epileptic
rats. The expression of JAK2 and STAT5a mRNAs and proteins in the myocardium of
epileptic rats was up-regulated in response to rhEPO, but not to CEPO pretreatment.
Moreover, AG490 treatment increased apoptotic rate, up-regulated caspase-3 protein
expression in the myocardium of epileptic rats.
Conclusions: Myocardial cell apoptosis may contribute to myocardial injury in
epilepsy. EPO protects myocardial cells from apoptosis via the JAK2/STAT5 pathway
in rats with experimentally induced epilepsy, whereas CEPO exerts an anti-apoptotic
action perhaps via a pathway independent of JAK2/STAT5 signaling.
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SIRT1-Mediated Epigenetic Downregulation of Plasminogen Activator
Inhibitor-1 Prevents Vascular Endothelial Replicative Senescence
Chen Houzao1, Wan Yanzhen1, Gao Peng1, Zhou Shuang1, Zhang Zhuqin1,
Hao Delong1, Lian Lishan2, Li Yongjun2, Liu Depei1
1State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical
Sciences, CAMS & PUMC, 2Department of Vascular Surgery, Peking Union Medical
College Hospital, Peking Union Medical College, CAMS & PUMC
Objectives: The inactivation of plasminogen activator inhibitor-1 (PAI-1) has been
shown to exert beneﬁcial effects in age-related vascular diseases, such as athero-
sclerosis. Limited information is available on the molecular mechanisms regarding the
negatively regulated expression of PAI-1 in the vascular system. SIRT1, a class III
histone deacetylase, plays a critical role in the control of endothelium-dependent
vascular tone and play a protective role in atherosclerotic vascular diseases. However,
it remains unclear whether SIRT1 prevents replicative vascular senescence and by
which SIRT1 facilitates the effects of anti-replicative senescence. Therefore, the
purpose of this study is to determine whether SIRT1 exerts its protective role in
replicative endothelial senescence via PAI-1 and elucidate the molecular mechanism
underlying protective effects in atherosclerosis.
Methods: We ﬁrst performed the correlation analysis between the expressions of
SIRT1 and PAI-1 in human atherosclerotic plaques and aortas of old mice. Next,
regulation of PAI-1 expression by SIRT1 was observed by adenovirus-mediated
overexpression in senescent human umbilical vein endothelial cells (HUVECs) or
RNAi in young HUVECs. Furthermore, manipulation on PAI-1 level by addition of
exogenous PAI-1 protein or inhibition of PAI-1 via its inhibitor PAI-039 was
introduced to determine whether the anti-senescent effect of SIRT1 was dependent on
PAI-1. Finally chromatin immunoprecipitation (ChIP) was used to clarify the
molecular mechanism of the regulation of PAI-1 by SIRT1.
Results: We observed an inverse correlation between SIRT1 and PAI-1 expression
in human atherosclerotic plaques and the aortas of old mice, suggesting that internal
negative regulation exists between SIRT1 and PAI-1. SIRT1 RNAi or inhibition by
EX527 increased PAI-1 expression and SA-b-gal activity in young HUVECs, while
adenovirus-mediated SIRT1 overexpression or activation by SRT1720 reversed the
increased PAI-1 expression in senescent HUVECs and aortas of old mice, accom-
panied by decreased SA-b-gal activity in vitro, and improved endothelial function
and reduced arterial stiffness in vivo. Moreover, addition of exogenous PAI-1 protein
blocked the protective effect of SIRT1 in senescent HUVECs while inhibition of
PAI-1 by PAI-039 ameliorated the senescence-promotional effect of SIRT1 RNAi
in young HUVECs, suggesting SIRT1-mediated inhibition of PAI-1 expression
contributes to the anti-aging effect of this protein in HUVECs. Furthermore, we
demonstrated that SIRT1 is able to bind to the PAI-1 promoter, resulting in a
decrease in the acetylation of histone H4 lysine 16 (H4K16) bound to the PAI-1
promoter region.
Conclusions: Taken together, our ﬁndings suggest that the SIRT1-mediated epige-
netic inhibition of PAI-1 expression exerts a protective effect in vascular endothelial
senescence and atherosclerosis.asic and Translational Medicine C85
